

Special Issue

Advanced Gastric Cancer

Message from the Guest Editors

In Western countries, the majority of gastric cancers (GC) is diagnosed in advanced stages reporting a 5-year survival rate of only 20–25%. In order to improve treatment strategy, a most accurate staging process should be completed. Availability of high-quality imaging and access to diagnostic laparoscopy with lavage cytology should be part of the diagnostic pathway for gastric cancer patients. Treatment of nonmetastatic, resectable, locally advanced gastric cancer is based on a combination of surgery and perioperative chemotherapy. In selected groups of patients with high risk of locoregional recurrence, (neo)adjuvant chemoradiotherapy should be considered. New epidemiological trends of GC in the Western countries include an upward shift in the location of the primary tumor and a relative increase of advanced and diffuse type tumors. These unsolved problems dictate the modification of multidisciplinary management towards a more individualized approach for the treatment of advanced GC.

Guest Editors

Prof. Dr. Wojciech Piotr Polkowski

Department of Surgical Oncology, Medical University of Lublin,
Radziwiłłowska 13, 20-080 Lublin, Poland

Dr. Johanna W. van Sandick

Department of Surgical Oncology, The Netherlands Cancer Institute -
Antoni van Leeuwenhoek Hospital, Postbus, 90203 1006 BE,
Amsterdam, The Netherlands

Deadline for manuscript submissions

closed (31 August 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/51535

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)